Search results for "Intravitreal injection"

showing 10 items of 42 documents

Intravitreal therapies for non-neovascular age-related macular degeneration with intraretinal or subretinal fluid

2017

OBJECTIVE: To evaluate the efficacy of intravitreal therapies in cases of atrophic age-related macular degeneration (AMD) with subretinal or intraretinal fluid. METHODS: A retrospective review was made of the clinical charts of patients diagnosed with atrophic AMD with subretinal or intraretinal fluid. Fundus photographs and spectral-domain optical coherence tomography images were examined, and an analysis was made on the presence of fluid and its density. Neovascularisation was ruled out by fluorescein and/or indocyanine green angiography. RESULTS: The study included 14 eyes from 13 patients with a mean age of 72.64 years and a mean follow-up of 80.5 weeks. Intraretinal fluid was observed …

MaleDegeneracion macular asociada a la edad no neovascularVisual acuityTriamcinolone acetonidegenetic structuresFluido subretinianoAngiogenesis InhibitorsFundus (eye)Triamcinolone0302 clinical medicineDegeneración macular asociada a la edad no neovascular Fluido intrarretiniano Fluido subretiniano Intraretinal fluid Intravitreal therapies Non-neovascular age related macular degeneration Spectral domain optical coherence tomography Subretinal fluid Terapias intravítreas Tomografía de coherencia óptica de dominio espectralFluorescein AngiographyTomografia de coherencia optica de dominio espectralAged 80 and overmedicine.diagnostic_testSubretinal FluidExudates and TransudatesGeneral MedicineFluorescein angiographyFluido intrarretinianoBevacizumabTreatment Outcomemedicine.anatomical_structureIntravitreal InjectionsFemalemedicine.symptomIntravitreal therapiesTomography Optical Coherencemedicine.drugSubretinal fluidmedicine.medical_specialtyBevacizumabRetinal DrusenRetinaSpectral domain optical coherence tomography03 medical and health sciencesNon-neovascular age related macular degenerationRanibizumabOphthalmologymedicineHumansAgedRetinabusiness.industryMacular degenerationmedicine.diseaseTerapias intravitreaseye diseasesSurgeryWet Macular Degeneration030221 ophthalmology & optometryIntraretinal fluidsense organsRanibizumabbusiness030217 neurology & neurosurgeryArchivos de la Sociedad Española de Oftalmología (English Edition)
researchProduct

Effectiveness of anti-vascular endothelial growth factors in neovascular age-related macular degeneration and variables associated with visual acuity…

2021

Objective To assess the overall effectiveness of anti-vascular endothelial growth factor (VEGF) therapy in treatment-naïve patients with neovascular age-related macular degeneration (nAMD) in a clinical practice setting. Study design EAGLE was a retrospective, 2-year, cohort observational, multicenter study conducted in Italy that analyzed secondary data of treatment-naïve patients with nAMD. The primary endpoint evaluated the mean annualized number of anti-VEGF injections at Years 1 and 2. The main secondary endpoints analyzed the mean change in visual acuity (VA) from baseline and variables associated with visual outcomes at Years 1 and 2. Results Of the 752 patients enrolled, 745 (99.07…

MaleEaglesAntiVEGF Drugs nAMD clinical practiceVisual AcuitySocial SciencesRetinal NeovascularizationInfographicsGeographical locationsMacular DegenerationMedical ConditionsEndocrinologyRetrospective StudieClinical endpoint80 and overPsychologyAged 80 and overEukaryotaItalyCohortMedicineHumanmedicine.medical_specialtyScienceDrug Administration ScheduleFollow-Up StudieSigns and Symptomsbiology.animalLinear regressionHumansAgedRetrospective StudiesSettore MED/30 - Malattie Apparato VisivoData VisualizationOrganismsBiology and Life Sciencesmedicine.diseaseOphthalmologyMacular DisordersLesionsEyesObservational studyClinical MedicinePeople and placesNeuroscienceVascular Endothelial Growth Factor AVisual acuityTime FactorsEye DiseasesVisionPhysiologyAngiogenesis InhibitorsMedicine and Health SciencesGeriatric OphthalmologyData ManagementMultidisciplinarybiologyQRetinal DegenerationRChartsEuropeAged; Aged 80 and over; Angiogenesis Inhibitors; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Intravitreal Injections; Italy; Macular Degeneration; Male; Retinal Neovascularization; Retrospective Studies; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual AcuityTreatment OutcomeVertebratesIntravitreal InjectionsRetinal DisordersSensory PerceptionFemalemedicine.symptomAnatomyAngiogenesis InhibitorResearch ArticleEagleComputer and Information SciencesTime FactorBirdsOcular SystemInternal medicineSettore MED/30Growth FactorsmedicineAnimalsEuropean UnionRaptorsEndocrine Physiologybusiness.industryIntravitreal InjectionCognitive PsychologyRetrospective cohort studyMacular degenerationGeriatricsAmniotesCognitive SciencePerceptionbusinessZoologyHeadFollow-Up Studies
researchProduct

Intravitreal aflibercept for the treatment of radiation-induced macular edema after ruthenium 106 plaque radiotherapy for choroidal melanoma.

2019

Purpose: To assess the efficacy of intravitreal aflibercept in patients suffering from post-radiation macular edema following plaque radiotherapy for choroidal melanoma. Methods: This prospective, interventional case series included patients affected by radiation maculopathy (RM) with macular edema secondary to ruthenium-106 plaque brachytherapy for choroidal melanoma. The effect of intravitreal aflibercept on best-corrected visual acuity (BCVA), central foveal thickness (CFT) detected by spectral domain optical coherence tomography (sd-OCT), and Horgan’s grading scale of RM was evaluated throughout the 24-month follow-up. Intraocular pressure (IOP) and possible complications were also reco…

MaleIntraocular pressureFovea CentralisVisual acuitygenetic structuresmedicine.medical_treatmentBrachytherapyVisual AcuityIntravitreal aflibercept; Plaque brachytherapy; Radiation maculopathy; Aged; Brachytherapy; Choroid Neoplasms; Dose-Response Relationship Drug; Dose-Response Relationship Radiation; Female; Fluorescein Angiography; Follow-Up Studies; Fovea Centralis; Fundus Oculi; Humans; Intravitreal Injections; Macular Edema; Male; Melanoma; Middle Aged; Prospective Studies; Receptors Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Ruthenium Radioisotopes; Tomography Optical Coherence; Treatment Outcome; Visual Acuity0302 clinical medicineEndophthalmitisReceptorsProspective StudiesFluorescein AngiographyTomographyMelanomaAfliberceptRadiationmedicine.diagnostic_testVascular Endothelial Growth FactorChoroid NeoplasmsMiddle AgedFluorescein angiographySensory SystemsTreatment OutcomeIntravitreal InjectionsFemaleIntravitreal aflibercept; Plaque brachytherapy; Radiation maculopathy; Aged; Brachytherapy; Choroid Neoplasms; Dose-Response Relationship; Drug; Dose-Response Relationship; Radiation; Female; Fluorescein Angiography; Follow-Up Studies; Fovea Centralis; Fundus Oculi; Humans; Intravitreal Injections; Macular Edema; Male; Melanoma; Middle Aged; Prospective Studies; Receptors; Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Ruthenium Radioisotopes; Tomography; Optical Coherence; Treatment Outcome; Visual Acuitymedicine.symptomIntravitreal afliberceptDrugRuthenium RadioisotopesTomography Optical CoherenceHumanmedicine.drugmedicine.medical_specialtyFundus OculiRecombinant Fusion ProteinsRuthenium RadioisotopeMacular EdemaFollow-Up StudieDose-Response Relationship03 medical and health sciencesCellular and Molecular NeuroscienceRadiation maculopathyOphthalmologymedicineHumansMacular edemaAgedFovea CentraliDose-Response Relationship Drugbusiness.industryPlaque radiotherapyIntravitreal InjectionPlaque brachytherapyDose-Response Relationship Radiationmedicine.diseaseeye diseasesProspective StudieOphthalmologyReceptors Vascular Endothelial Growth FactorOptical Coherence030221 ophthalmology & optometryMaculopathysense organsbusinessChoroid Neoplasm030217 neurology & neurosurgeryRecombinant Fusion ProteinFollow-Up StudiesGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
researchProduct

Retrograde neurotrophic signaling in rat retinal ganglion cells is transmitted via the ERK5 but not the ERK1/2 pathway.

2014

Purpose Neurotrophic deprivation is considered an important event in glaucomatous retinal ganglion cell (RGC) death. However, the mitogen-activated protein kinase (MAPK) pathway transmitting axonal neurotrophic signals in RGC has not been identified. We investigated the involvement of ERK5 and ERK1/2 in retrograde axonal neurotrophic signaling in rats. Methods Adult Sprague-Dawley rats were used. Retinal immunostaining for ERK5 and MEK5 was performed. Levels of total and phosphorylated ERK5 and ERK1/2 were analyzed in retinal lysate by quantitative Western blotting. The effects of age, brain-derived neurotrophic factor (BDNF) stimulation at RGC soma (intravitreal injection) or axon ending (…

MaleRetinal Ganglion Cellsmedicine.medical_specialtyAgingSuperior ColliculiMAP Kinase Signaling SystemBlotting WesternRetinal ganglionRetinaRats Sprague-Dawley03 medical and health sciences0302 clinical medicineNeurotrophic factorsInternal medicinemedicineAnimalsAxonPhosphorylationMitogen-Activated Protein Kinase 7030304 developmental biologyBrain-derived neurotrophic factorMitogen-Activated Protein Kinase 10303 health sciencesRetinaMitogen-Activated Protein Kinase 3biologyChemistryBrain-Derived Neurotrophic FactorBrainAnatomyRatsmedicine.anatomical_structureEndocrinologynervous systemRetinal ganglion cellTrk receptorOptic Nerve InjuriesIntravitreal Injectionsbiology.proteinsense organsNeuroglia030217 neurology & neurosurgeryNeurotrophinInvestigative ophthalmologyvisual science
researchProduct

Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema: the dexcat stu…

2020

Purpose: To report clinical outcomes of two different timings of intravitreal dexamethasone (DEX) implant administration for prevention of diabetic macular oedema (DME) worsening following cataract surgery. Methods: This multicentre, retrospective study included patients with DME who received an intravitreal DEX implant 1 month before cataract surgery, ‘precataract DEX’ group, or at the time of cataract surgery, ‘concomitant treatments’ group. Inclusion criteria were a follow-up ≥3 months and ophthalmological examination with optical coherence tomography (OCT) imaging at baseline (cataract surgery) and throughout follow-up. Anatomical improvement was considered to be a decrease in OCT centr…

MaleTime FactorsVisual acuitygenetic structuresmedicine.medical_treatmentVisual AcuityDexamethasone0302 clinical medicinedexamethasone implantDrug Implantsdiabetescataract surgeryGeneral MedicineTreatment Outcomediabetic macular oedemaIntravitreal InjectionsFemalecataract surgery; dexamethasone implant; diabetes; diabetic macular oedemamedicine.symptomTomography Optical Coherencemedicine.drugmedicine.medical_specialtyCataract ExtractionCataractMacular Edema03 medical and health sciencesOphthalmologyDiabetes mellitusmedicineHumansAdverse effectGlucocorticoidsDexamethasoneAgedRetrospective StudiesDiabetic RetinopathySettore MED/30 - Malattie Apparato Visivobusiness.industryRetrospective cohort studyCataract surgerymedicine.diseaseeye diseasesOphthalmologydiabeteConcomitant030221 ophthalmology & optometryImplantbusiness030217 neurology & neurosurgeryFollow-Up StudiesActa Ophthalmologica
researchProduct

Outcomes of cataract surgery in diabetic patients: results of the Pan American Collaborative Retina Study Group.

2014

Purpose: This study was designed to evaluate the visual and anatomical outcomes after cataract surgery in diabetic patients with different intraoperative therapeutic strategies. Methods: The research design comprised of a multicentric, retrospective, interventional study conducted at 6 centers in Argentina, Brazil, Costa Rica, Puerto Rico, Spain, and Venezuela. We included 138 diabetic patients with at least 6-month follow-up following phacoemulsification and intraocular lens implantation. Best-corrected visual acuity (BCVA) and central subfield thickness were collected at baseline and at 1-, 2-, 3-, and 6-month follow-up. Of these, 42 cases were not treated with any intraoperative coadjuva…

MaleVascular Endothelial Growth Factor ATriamcinolone acetonideVisual acuitygenetic structuresmedicine.medical_treatmentExtração de catarataVisual AcuityIntraocular lensCuidados intraoperatóriosAngiogenesis InhibitorsTriamcinolonelcsh:OphthalmologyLens Implantation IntraocularDiabetic retinopathyAntibodies monoclonalAged 80 and overGeneral MedicineDiabetic retinopathyMiddle AgedMulticenter studyBevacizumabTreatment OutcomeCataract extractionChemotherapy AdjuvantEstudo multicêntricoIntravitreal InjectionsFemalemedicine.symptommedicine.drugAdultmedicine.medical_specialtyBevacizumabAntibodies Monoclonal HumanizedCataractMacular EdemaIntraoperative careOphthalmologyEdema macularmedicineAnticorpos monoclonaisHumansMacular edemaGlucocorticoidsAgedRetrospective StudiesMacular edemaDiabetic RetinopathyIntraoperative CarePhacoemulsificationbusiness.industryRetinopatia diabéticaPhacoemulsificationCataract surgeryFacoemulsificaçãomedicine.diseaseSurgeryImplante de lente intraocularOphthalmologyLens implantation intraocularlcsh:RE1-994businessFollow-Up StudiesArquivos brasileiros de oftalmologia
researchProduct

A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.

2014

AIMS: The aim was to compare the efficacy of intravitreal therapy with bevacizumab and ranibizumab for choroidal neovascularization (CNV) in pathologic myopia (PM). METHODS: This was a prospective multicenter randomized nonblinded trial. RESULTS: In seven centers, 78 eyes were randomized 1:1 to treatment with bevacizumab (group B, 40 eyes) or ranibizumab (group R, 38 eyes) given with an "on demand" regimen (PRN). The mean follow-up was 19 months (SD 2, range 12-24). The mean BCVA at baseline was 0.60 logMAR (20/80 Snellen equivalent, Seq) and 50 letter score (ls). Mean final BCVA was 0.51 LogMAR (20/63 Seq) and 57 ls (p = 0.0009 and p = 0.0002, respectively). In group B, mean basal BCVA was…

MaleVascular Endothelial Growth Factor AVisual Acuity/drug effectsVisual acuitygenetic structuresVisual AcuityAngiogenesis Inhibitorslaw.inventionBevacizumab/therapeutic use0302 clinical medicineRandomized controlled triallawMyopiaMedicineProspective StudiesProspective cohort studyPathological myopiaAged 80 and overMiddle AgedSensory SystemsBevacizumabVascular endothelial growth factor AChoroidal neovascularizationIntravitreal InjectionsMyopia DegenerativeFemalemedicine.symptommedicine.drugAdultmedicine.medical_specialtyBevacizumabNeuroscience(all)CNVBevacizumab; CNV; Pathological myopia; Ranibizumab.Antibodies Monoclonal HumanizedRanibizumab/therapeutic use03 medical and health sciencesCellular and Molecular NeuroscienceOphthalmologyRanibizumabVascular Endothelial Growth Factor A/antagonists & inhibitorsHumansAngiogenesis Inhibitors/therapeutic useIntravitreal bevacizumabAgedpathological myopia CNV bevacizumab ranibizumabSettore MED/30 - Malattie Apparato Visivobusiness.industryTherapeutic effectChoroidal Neovascularization/drug therapyeye diseasesChoroidal NeovascularizationOphthalmologyRegimen030221 ophthalmology & optometryMyopia Degenerative/drug therapysense organsRanibizumabbusiness030217 neurology & neurosurgeryFollow-Up StudiesGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
researchProduct

Assessment of intravitreal anti-VEGF drugs and dexamethasone for retinal diseases in real world setting: A multi-centre prospective study from Southe…

2022

Describe drug utilisation and clinical outcomes of intravitreal anti-VEGF drug and dexamethasone use in the real-world setting in Southern Italy using data from multi-centre study of retinal disease. Clinical data of retinal disease patients treated with anti-VEGF drugs and dexamethasone implant in 6 out-patient ophthalmology centres from Southern Italy were collected by means of an electronic case report form. Patients receiving at least one intravitreal injection/implant of the study drugs were followed for up to two years and described in terms of demographics and clinical characteristics. Drug utilisation patterns were described. A sign-rank test was used to compare clinical data on vi…

MaleVascular Endothelial Growth Factor Agenetic structuresPharmacology &ltPHARMACOLOGY diabetic macular edema &ltbiostatisticsAngiogenesis InhibitorsDexamethasoneMacular DegenerationCATARACTRetinal DiseasesRanibizumabRetinal Vein OcclusionHumansProspective StudiesRETINAAgedAged 80 and overPharmacologySettore MED/30 - Malattie Apparato Visivopathologic myopiaGeneral MedicineMiddle AgedBevacizumabOphthalmologyLENSRETINA epidemiology / biostatistics pathologic myopia retina - medical therapies &ltIntravitreal InjectionsPharmacology diabetic macular edema RETINA epidemiology biostatisticsLENSCATARACTpathologic myopiaFemaleepidemiologydiabetic macular edemaEuropean Journal of Ophthalmology
researchProduct

Postoperative endophthalmitis incidence after intravitreal therapy: a comparison of two different preoperative antibiotic prophylaxis.

2016

Prevention of postoperative endophthalmitis (POE) is a goal of every ophthalmic procedure and also in intravitreal therapy (IVT). This comparative retrospective study targets whether systemic and topical preoperative antibiotic prophylaxis (PAP) regimen does prevent POE after IVT in a higher rate compared with topical PAP alone. Out of 6111 IVT performed over a period of 103.5 months, in the study group A patients were treated with systemic and topical PAP (2881 IVT), and in the study group B patients were treated only with topical PAP (3230 IVT). Intravitreal drugs were anti-VEGF, triamcinolone and dexamethasone implants. The incidence of POE in group A (1/2881 or 0.035 % per injection) wa…

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyTriamcinolone acetonideAngiogenesis InhibitorsTriamcinolone AcetonideGroup BDexamethasone03 medical and health sciences0302 clinical medicineEndophthalmitisPostoperative ComplicationsAntibiotic prophylaxiPreoperative CaremedicineHumansEndophthalmitiAntibiotic prophylaxisGlucocorticoidsDexamethasoneAgedRetrospective StudiesAged 80 and overDrug ImplantsEndophthalmitisDose-Response Relationship DrugSettore MED/30 - Malattie Apparato Visivobusiness.industryIncidence (epidemiology)IncidenceIntravitreal therapyRetrospective cohort studyAntibiotic ProphylaxisMiddle Agedmedicine.diseaseSurgeryAnti-Bacterial AgentsOphthalmologyRegimenAnesthesiaIntravitreal Injections030221 ophthalmology & optometryFemalebusiness030217 neurology & neurosurgerymedicine.drugInternational ophthalmology
researchProduct

Outcomes of treatment of pediatric choroidal neovascularization with intravitreal antiangiogenic agents: the results of the KKESH International Colla…

2014

Purpose: To evaluate safety and clinical results of intravitreal antiangiogenic agents for choroidal neovascularization in pediatric patients. Methods: Retrospective, multicenter, interventional case series. A total of 45 eyes of 39 pediatric patients with choroidal neovascularization of various etiologies were treated with intravitreal injection of antiangiogenic agents (1.25 mg per 0.05 mL of bevacizumab or 0.5 mg per 0.05 mL of ranibizumab). Results: There were 24 girls and 15 boys with group median age of 13 years (range, 3–17 years). Mean follow-up period was 12.8 months (range, 3–60 months). Median visual acuity in terms of logarithm of the minimum angle of resolution at presentation …

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresBevacizumabAdolescentVisual AcuityAngiogenesis InhibitorsAntibodies Monoclonal HumanizedOphthalmologyRanibizumabmedicineHumansChildRetrospective StudiesRetinabusiness.industryRetrospective cohort studyGeneral Medicineeye diseasesChoroidal NeovascularizationClinical trialBevacizumabOphthalmologyChoroidal neovascularizationmedicine.anatomical_structureTreatment OutcomeChild PreschoolIntravitreal InjectionsEtiologyFemalesense organsmedicine.symptomRanibizumabbusinessTomography Optical Coherencemedicine.drugFollow-Up StudiesRetina (Philadelphia, Pa.)
researchProduct